ClinicalTrials.Veeva

Menu

Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device

P

phenox

Status

Completed

Conditions

Intracranial Aneurysm

Study type

Observational

Funder types

Industry

Identifiers

NCT02600364
DP64/BO1507

Details and patient eligibility

About

The purpose of this study is to assess safety and effectiveness of the p64 Flow Modulation Device.

Full description

Title: Diversion-p64. Device: p64 Flow Modulation Device. Study design: Prospective, multicenter, single arm Post Market Clinical Follow-Up Study.

Purpose: To assess safety and effectiveness of p64. Study duration: 48 months. Sample Size: 400 patients. Number of sites: > 20. Follow-up intervals: Two independent follow-ups (after 3-6 and 7-12 months) according to site specific standard.

Enrollment

450 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  1. Age ≥ 18
  2. Patient harbours either one saccular or one dissecting or one blisterlike or one fusiform intracerebral aneurysm or one intracerebral segmental disease, in the anterior circulation for which the indication for p64 treatment is given
  3. Patient or legal representative provides written informed consent verifying that he/she consents to the use of his/her data (according to the data protection laws)

Exclusion Criteria

  1. Aneurysms of the posterior circulation
  2. Imaging evidence of bifurcation aneurysms
  3. Imaging evidence of dissections
  4. Imaging evidence of fistulae
  5. Imaging evidence of arteriovenous malformations
  6. Patient is harbouring another aneurysm that has to be treated within six months after first procedure
  7. Known allergy to study medication, e.g. ASA, Clopidogrel, Heparin or contrast media
  8. Confirmation of positive pregnancy test according to site specific standard of care (e.g. test, verbal communication)
  9. Current involvement in another study or trial
  10. Parent vessel treated with other Flow Diverters than p64 during intervention and re-treatment

Trial contacts and locations

26

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems